A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Inclusion Criteria:

• Male or female Japanese subjects at least 20 years of age at the time of informedconsent

• Type 2 diabetes subjects (diagnosed clinically) for at least 6 months prior toscreening

• HbA1c 7.5-10.0% [58 mmol/mol-86 mmol/mol] (both inclusive)

• Subjects on stable therapy with one OAD (oral antidiabetic drug) (stable therapy isdefined as unchanged medication and unchanged dose) for for at least 60 days beforescreening according to approved Japanese labelling

Exclusion Criteria:

• Treatment with insulin within 12 weeks prior to screening

• Treatment with any medication for the indication of diabetes or obesity other thanstated in the inclusion criteria in a period of 60 days before screening

• Screening calcitonin equal or above 50 ng/l

• History of pancreatitis (acute or chronic)

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrineneoplasia type 2 (MEN 2)

• Subjects presently classified as being in New York Heart Association (NYHA) Class IV

• Within the past 180 days any of the following: myocardial infarction, stroke orhospitalisation for unstable angina and/or transient ischemic attack

• Diagnosis of malignant neoplasms within the last 5 years (except basal and squamouscell skin cancer, polyps and in-situ carcinomas)

• Any condition which, in the opinion of the investigator might jeopardise subject'ssafety or compliance with the protocol